Replies to post #175824 on Anavex Life Sciences Corp (AVXL)

[OFP]

I, as I am sure you, have searched high and low for clinical trial results based on tests focused on an S1R Agonist in humans. There is I believe only one small trial in related trial in humans for neuropathic pain, which if I recall right was inconclusive but indicating further trials would be justified.

Hence the Anavex trials are really the first in humans and supported by a raft of preclinical work.

I'm not sure of the trial you are referring to but sounds interesting. However, I view any trial of DZP, dextromethorphan, fluvoxamine, and other compounds which are S1R agonists (with other actions was well) as adding insight into the effect S1R agonism is likely to have. For example, dextromethorphan has shown strong results for peripheral neuropathic pain but then failed in addressing central neuropathic pain.

I think it's a bit misleading to say AVXL trials are the first...they are taking an S1R agonist/cholinomimetic and trying it in AD...phrased that way, that's the same profile as DZP (with the difference being in how the cholinomimetic effect is delivered). DZP and DM have been tried in PD. DM tried in Rett. Results of all of those are instructive and worthy of examination to see what to look for in the hopes of a differential effect. Of course, teasing out differential effects due to S1R alone vs. their other pharmacologic actions is difficult but a worthy endeavor none-the-less.

Happy Holidays.